NCT05210413
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05210413
Title Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (SPARTO)
Acronym SPARTO
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University Hospital, Bordeaux
Indications
Therapies
Age Groups: child | senior | adult
Covered Countries FRA

Facility Status City State Zip Country Details
CHU d'Angers - Unité d'Hématologie et d'Oncologie pédiatrique Angers France Details
CHU de Bordeaux - Unité d'Hématologie et d'Oncologie pédiatrique Bordeaux 33076 France Details
Institut Bergonié - Oncologie Médicale Bordeaux 33076 France Details
Centre Oscar Lambret - Oncologie pédiatrie Lille 59020 France Details
Oscar Lambret Center Lille France Details
Centre Léon Bérard - Oncologie Médicale Lyon 69373 France Details
Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP) - Oncologie pédiatrique Lyon 69373 France Details
APHM Hôpital des Enfants La Timone - Hématologie Oncologie Pédiatrique Marseille 13385 France Details
Nantes University Hospital Nantes France Details
Institut Curie - Centre D'Oncologie SIREDO Paris 75005 France Details
Curie Institute Paris France Details
Strasbourg University Hospital Strasbourg France Details
Gustave Roussy - Oncologie pédiatrique Villejuif 94805 France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field